Boehringer Ingelheim’s glucagon/GLP-1 dual agonist has driven 16.6% weight loss at Week 76 of a phase 3 study. While the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results